

Disclaimer :

The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.

M. 9554 ELANCO ANIMAL HEALTH / BAYER ANIMAL HEALTH DIVISION

SECTION 1.2

Description of the concentration

On 20 August 2019, Elanco Animal Health Inc. (“**Elanco**”) and Bayer AG entered into a share and asset purchase agreement that provides for the acquisition by Elanco of the Bayer AG animal health business (“**BAH**”).

Elanco is a US-headquartered animal health company and active internationally. Bayer AG is a life sciences company with a number of business segments, including animal health, headquartered in Germany and active internationally. Both Elanco and BAH develop, manufacture and market products for companion and production animals.